FDA approves AstraZeneca, Sanofi shot that protects infants and toddlers against RSV

The Food and Drug Administration on Monday approved AstraZeneca and Sanofi 's shot that protects infants and toddlers against respiratory syncytial virus, which is the leading cause of hospitalization among infants in the U.S. Nirsevimab is the first shot approved by the FDA to protect all infants against RSV regardless of whether they are healthy or have a medical condition. The FDA approval of nirsevimab comes several months ahead of RSV season this fall. The Centers for Disease Control and Prevention's panel of independent experts will meet in August to...